Table 1.
Patient characteristics
| Enrolled patients (SRT + docetaxel, n = 19) | Matched pairs (SRT alone, n = 19) | P value | |
|---|---|---|---|
| Age at SRT | |||
| Median (minimum-maximum) | 66.6 (43.6-78.9) | 66.9 (49.3-76.1) | .17 |
| Follow-up post-SRT, y | |||
| Median (IQR) | 4.7 (4.6-5.3) | 6.1 (4.5-7.1) | .04 |
| Pre-SRT PSA (ng/mL) | |||
| Median (IQR) | 0.7 (0.4-1.3) | 0.5 (0.4-1.5) | .07 |
| Pre-SRT PSA doubling time, mo | |||
| Median (IQR) | 9.5 (5.2-15.1) | 11.8 (4.9-21.5) | .6 |
| Post-SRT PSA nadir (ng/mL) | |||
| Median (IQR) | 0 (0-0.3) | 0.1 (0.0-0.6) | .3 |
| PSA nadir ≤0.1 ng/dL | |||
| No. of patients (%) | 12 (63.2%) | 11 (57.9%) | 1.0 |
| SRT dose (Gy) | .5 | ||
| 64.8 | 10.5% | 26.3% | |
| 68.4 | 57.9% | 47.4% | |
| 0.2 | 31.6% | 26.3% | |
| Gleason score | .17 | ||
| 2-6 | 5.3% | 21.0% | |
| 7 | 52.6% | 47.4% | |
| 8-10 | 42.1% | 31.6% | |
| +SM | 26.3% | 31.6% | 1.0a |
| SVI | 15.8% | 15.8% | 1.0 |
| ECE | 21.1% | 36.8% | .4 |
| +SM or SVI or ECE | 50.0% | 61.1% | .6 |
| +LN | 5.3% | 0.0% | .9 |
ECE, extracapsular extension; IQR, interquartile range; LN, lymph node; PSA, prostate-specific antigen; SM, surgical margin; SRT, salvage radiation therapy; SVI, seminal vesicle invasion.
a
1 SRT + docetaxel patient is missing these data, but this did not impact the Stephenson calculation. This pair is excluded from the testing.